DCAF16

Across TCGA pan-cancer cohorts, DCAF16 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated DCAF16 data layer compared with 2 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DCAF16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCAF16 expression acts as an unfavorable survival marker, although some lineages such as READ and UCS show a favorable association.

LIHC, READ, and UCS are the cancer types where DCAF16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.461	0.621	<.001	101	view →
READ	OS	Tertile	II,III,IV	0.892	0.301	<.001	75	view →
UCS	DFS	Median	IV	0.952	0.367	.001	74	view →
BRCA	OS	Median	All	0.953	0.895	<.001	74	view →
KIRP	DFS	Median	All	0.808	0.919	.008	43	view →
SCLC	DFS	Median	II,III,IV	0.819	0.205	.004	33	view →
LGG	OS	Median	All	0.617	0.409	<.001	30	view →
THCA	OS	Median	II,III,IV	0.856	0.979	.014	24	view →
UVM	DFS	Tertile	III,IV	0.091	1.000	.004	23	view →
CHOL	OS	Tertile	All	1.000	0.187	.012	15	view →
SARC	OS	Median	All	0.652	0.854	<.001	13	view →
LUSC	OS	Tertile	All	0.830	0.723	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

DCAF16–LIHC (DFS)

Open the LIHC breakdown →